In a landscape where healthcare organizations typically function as consumers of enterprise software, a groundbreaking partnership has emerged that challenges the status quo. NYU Langone Health and the Dana-Farber Cancer Institute have officially launched the "Solavia Decision Suite," a sophisticated, homegrown digital oncology tool designed to streamline the complex process of cancer treatment selection. By shifting from the role of mere end-users to active software developers, these two powerhouses of medical research are attempting to solve a perennial problem in oncology: the rapid obsolescence of clinical research data and the resulting difficulty in applying it to patient-specific care.
The Genesis of Solavia: A Strategic Pivot
The origins of Solavia are rooted in necessity. Both institutions previously relied on a third-party oncology pathway tool provided by Philips. However, when Philips made the strategic decision to sunset its oncology business unit, NYU Langone and Dana-Farber were left at a crossroads: search for a new, potentially ill-fitting vendor or take matters into their own hands.
The resulting collaboration leveraged the unique strengths of each institution. Dana-Farber provided the deep clinical informatics and rigorous medical content curation necessary for high-stakes oncology decisions, while NYU Langone contributed its advanced product development life cycle and technical infrastructure. The objective was to create a "next-generation" platform that could synthesize vast amounts of clinical research, oncology guidelines, and patient data into a seamless, actionable interface.
Chronology of Development and Deployment
The development of Solavia was characterized by a rapid, iterative approach designed to ensure clinical efficacy before broader market release.
- Pre-2026: Both organizations identified the limitations of existing vendor-led oncology tools, noting that clinicians often felt burdened by software that didn’t fully integrate with their daily workflows.
- Early 2026: Following the decision to end their relationship with the third-party provider, leadership at both institutions initiated a formal partnership to co-develop an in-house alternative.
- June 2026: NYU Langone initiated a successful internal pilot of the Solavia Decision Suite. This phase served as a "discovery" period, where oncology specialists provided constant feedback, allowing engineers to refine the UI/UX to match the actual speed and complexity of clinical decision-making.
- Late 2026/Early 2027: Having validated the platform internally, the institutions made the rare decision to commercialize the product, offering it as a SaaS (Software as a Service) solution to other health systems.
Supporting Data: Why "Build vs. Buy" is Gaining Traction
The decision by NYU Langone and Dana-Farber is part of a broader, emerging trend in the healthcare sector. For years, hospitals have been tethered to massive, expensive enterprise software stacks—many of which offer bloated feature sets where organizations utilize only 30% of the functionality while paying for 100% of the cost.
Furthermore, the "build" argument is increasingly supported by the maturation of cloud computing and AI-assisted development. Nader Mherabi, executive vice president and chief digital and information officer at NYU Langone, notes that the barrier to entry for custom software development has lowered significantly. Cloud-based platforms now allow for modular, scalable architectures that were previously too costly or technically cumbersome for individual hospital systems to maintain.
This movement is not limited to oncology. In March 2026, Geisinger Health System similarly launched "MyCode Connect," a bespoke genomic medicine platform designed to integrate precision medicine tools directly into the clinical workflow. These examples suggest that as specialty care becomes more data-intensive, the "one-size-fits-all" model of major EHR vendors may no longer suffice.
Official Perspectives: The Philosophy of Clinical Integration
In an exclusive interview with Healthcare Dive, Nader Mherabi highlighted the primary driver for this shift: the physician’s time.
"For oncologists to decide which chemotherapy a patient receives is a complex matter because oncology research changes quite a bit," Mherabi explained. "The beauty of creating a product of this variety is that it can be highly integrated into the clinician workflow."
When asked why the institutions chose to move into the commercial space rather than keeping the tool proprietary, Mherabi emphasized the importance of validation. "We wanted to launch it for ourselves and then prove to other health systems that it truly works. They can come and actually see a working product in our institution."
He further noted that the governance structure is robust, involving legal, compliance, and venture teams from both organizations to ensure that Solavia is "multi-tenant." This means that while the platform is shared, the data of every institution remains strictly segregated and secure—a mandatory requirement for any health system adopting external digital tools.
Technical Implications: Scalability and Workflow Optimization
Solavia’s architecture was designed specifically to address the "multi-nested" nature of oncology pathways. In a clinical setting, a physician cannot afford to navigate through five different windows to find a specific treatment guideline. By integrating the suite directly into the electronic health record (EHR)—specifically leveraging the infrastructure of systems like Epic—Solavia ensures that the most recent, evidence-based research is presented at the exact moment a treatment decision is being made.
The platform is designed to be EHR-agnostic, meaning that while it thrives within Epic, it can technically be integrated with other systems or deployed as a standalone tool. This flexibility is critical for health systems that may not have the same technical footprint as NYU Langone but still require advanced decision-support capabilities.
Strategic Implications for Health Systems
The launch of Solavia forces a re-evaluation of how health systems view their relationship with technology vendors. For years, the industry has been reliant on the "Big Tech" approach to medical software. However, the high costs of these enterprise suites, combined with their inability to adapt quickly to medical breakthroughs, have created a vacuum that institutions like NYU Langone and Dana-Farber are now filling.
Key Considerations for Future Developers:
- The "Niche" Necessity: Health systems should only consider building software when there is a clear, underserved niche where existing products fail to deliver. Attempting to build a general-purpose EHR from scratch remains an impossible task for most.
- Resource Allocation: Building requires not just capital, but an organizational culture that supports "product life cycle" thinking. NYU Langone’s established technology ventures arm provided the necessary scaffolding to bridge the gap between clinical care and product commercialization.
- Governance as a Foundation: Any institution looking to follow this path must have a rigorous governance framework. Security reviews, data privacy, and multi-tenant integrity are the primary hurdles that will dictate whether a homegrown tool is viable for external use.
- The AI Tailwind: As Mherabi noted, the acceleration of software development through AI means that custom-built tools are no longer decade-long projects. Smaller teams can now achieve high-performance results in a fraction of the time, provided they have access to domain-expert clinicians who can guide the development.
Conclusion: A New Era for Medical Technology
The collaboration between NYU Langone and Dana-Farber represents more than just a new software tool; it represents a fundamental change in the identity of the modern hospital. By proving that they can build, deploy, and commercialize high-level clinical decision support, these institutions are signaling to the market that the era of passive dependence on external vendors is ending.
While it is unlikely that every health system will become a software company, those that have the resources and the clinical depth to innovate are increasingly choosing to take control of their own technological destinies. As Solavia begins its rollout to other health systems, the industry will be watching closely to see if this model of "clinician-led, researcher-guided" software development becomes the new gold standard for specialty care.
For now, the message from NYU Langone and Dana-Farber is clear: when the tools available to you are no longer sufficient to meet the challenges of modern medicine, the best course of action is to build the future yourself.
